Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

Kayla V. Myers 1,2*, Sarah R. Amend 2 and Kenneth J. Pienta 1,2,3,4

Abstract
Tumor-associated macrophages are an abundant cell type in the tumor microenvironment. These macrophages serve as a promising target for treatment of cancer due to their roles in promoting cancer progression and simultaneous immunosuppression. The TAM receptors (Tyro3, Axl and MerTK) are promising therapeutic targets on tumor-associated macrophages. The TAM receptors are a family of receptor tyrosine kinases with shared ligands Gas6 and Protein S that skew macrophage polarization towards a pro-tumor M2-like phenotype. In macrophages, the TAM receptors also promote apoptotic cell clearance, a tumor-promoting process called efferocytosis. The TAM receptors bind the “eat-me” signal phosphatidylserine on apoptotic cell membranes using Gas6 and Protein S as bridging ligands. Post-efferocytosis, macrophages are further polarized to a pro-tumor M2-like phenotype and secrete increased levels of immunosuppressive cytokines. Since M2 polarization and efferocytosis are tumor-promoting processes, the TAM receptors on macrophages serve as exciting targets for cancer therapy. Current TAM receptor-directed therapies in preclinical development and clinical trials may have anti-cancer effects though impacting macrophage phenotype and function in addition to the cancer cells.

Keywords: Macrophage, TAM receptors, Tyro3, Axl, MerTK, Efferocytosis, M2 macrophage polarization

Background
Cancer is one of the leading causes of death worldwide. In the United States, 1,762,450 new cases and 606,880 cancer-related deaths are estimated to occur in 2019 [1]. Disease progression is strongly influenced by the tumor microenvironment (TME), comprised of all host cells and components beyond the cancer cells [2–5]. The TME is made of blood vessels, extracellular matrix (ECM) and many different host cell types including fibroblasts, B cells, and T cells. Tumor-associated macrophages are a critical component of the TME. In general, these macrophages have tumor-promoting functions such as tumor initiation, growth, angiogenesis, metastasis, immunosuppression and resistance to therapy [6]. Elucidating the role of macrophages in tumor biology is crucial as modulating their activity may open new opportunities for therapeutic interventions. Likewise, it is also important to understand how macrophages in the TME are impacted by current therapies aimed at targeting cancer cells.

Macrophages have diverse roles under normal physiologic conditions including phagocytosis, antigen-presentation and modulation of the immune response [7, 8]. There are different subtypes of macrophages that play unique and related roles in both normal and disease states. M2 macrophages support tissue homeostasis, wound-healing and resolution of inflammation. Tumor-associated macrophages are largely polarized to an alternatively-activated, M2-like state. In the TME, M2-like macrophages exert pro-tumor effects via their wound-healing functions. For example, M2 macrophages promote angiogenesis through secretion of pro-angiogenic factors [9, 10]. M2 macrophages suppress T cell infiltration and cytotoxic T cell function which impairs the anti-tumor immune response [11–13]. M2 tumor-associated macrophages also promote invasion and metastasis of cancer cells through ECM remodeling [14].
Another M2-associated function is phagocytosis of apoptotic cells, i.e., efferocytosis. Efferocytosis is enacted to resolve inflammation, repair tissue and suppress the immune system. In the TME, these effects promote tumor growth, metastasis and evasion of anti-tumor immunity [15, 16]. Thus, targeting tumor-associated macrophages and their function are potential therapeutic strategies due to their large influence in disease progression.

The TAM receptors (Tyro3, Axl and MerTK) are a well-studied family of receptors that, in addition to their function in many other cell types, including cancer cells, play roles in macrophage polarization and efferocytosis. The role of the TAM receptors in macrophages was first discovered upon the generation of TAM receptor single, double and triple knockout mice [17]. At approximately 4 weeks of age, the spleens and lymph nodes of the triple knockout mice were substantially larger compared to wild type (WT) mice due to hyperproliferation of constitutively active B and T lymphocytes. The triple knockout mice also developed autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus [18]. These phenotypes were found to be due to altered macrophage and dendritic cell function. Following this work, the role of the TAM receptors on macrophages in different tissues and disease states has been studied. This review will summarize macrophage TAM receptor function in the context of the TME and discuss implications for interventions in cancer therapy.

Main text

The TAM receptor family and their ligands

The TAM receptor family is comprised of three receptor tyrosine kinases that share similar structures distinct from other receptor tyrosine kinases (Fig. 1a). Each receptor’s extracellular domain contains two immunoglobulin-like (IgL) repeats and two fibronectin type III (FNIII) repeats. This is followed by a single helix transmembrane domain and the cytoplasmic tyrosine kinase domain (TKD) containing the KW(I/L)A(I/L)ES consensus sequence [19]. Axl was the first of this family discovered in studies identifying genes that transform NIH 3 T3 cells [20, 21]. MerTK was originally identified as the oncogene v-ryk from avian retroviruses and recognized as a member of the Axl family when the murine form was cloned [22, 23]. Tyro3 was the last of the three proteins to be added to the TAM receptor family based on its shared homology [24]. There are multiple alternative names for each in the published literature, and for clarity the names Tyro3, Axl and MerTK will be used throughout this review regardless of the naming convention used in the referenced literature. Axl is also known as UFO, Tyro7, JTK11 and ARK. MerTK is also referred to as MER, RP38, c-Eyk, c-mer, and Tyro12. Tyro3 can also be called RSE, BYK, Etk-2, Dtk, Rek, Sky and Tif.

The TAM receptors are activated upon binding of their extracellular ligands. Gas6 and Protein S were the first discovered and are the most studied ligands for the TAM receptors. Gas6 was identified as one of the upregulated “growth arrest-specific” genes following serum starvation of NIH 3 T3 cells [25]. Gas6 was then confirmed in humans and recognized to have strong homology with Protein S [26, 27]. Protein S, also known as Pros1, is a Vitamin K dependent protein that has TAM receptor-independent roles in the blood coagulation cascade [28, 29]. As depicted in Fig. 1b, the amino terminus Gas6 and Protein S have a γ-carboxyglutamic acid (Gla) domain followed by four epidermal growth factor (EGF)-like repeats. Adjacent to the carboxy terminus are two laminin G (LG)-like domains that share sequence similarity to the sex hormone-binding protein (SHBP) [27]. Unique to Protein S is a thrombin sensitive cleavage site between the Gla and EGF-like domains [30]. While at first unclear, it is now understood that Gas6 binds all three receptors, whereas Protein S only activates Tyro3 and MerTK [27, 31–33]. There are three newly discovered ligands of the TAM receptors: Tubby and galecin-3, which bind MerTK, and Tubby-like protein 1 (Tulp-1) which binds all three receptors [34–36]. Due to the recentness of these TAM receptor ligand discoveries, not much much information regarding their function is known compared to that of Gas6 and Protein S and this review will largely focus on the effects of ligands Gas6 and Protein S.

TAM receptor-mediated signaling

Consistent with other receptor tyrosine kinases (RTKs), the TAM receptors become activated following ligand binding, receptor dimerization and subsequent trans-autophosphorylation of the kinase domains to activate intracellular signaling cascades and modulate gene transcription. More specifically, the TAM receptors are activated upon IgL domain binding to the LG-like domains of their ligand [37, 38]. Prior to activation, glutamic acid γ-carboxylation of the Gla domain the ligand Gas6 or Protein S is required [39].

The lipid membrane molecule phosphatidylserine (PtdSer) has been shown to strengthen ligand binding affinity and TAM receptor mediated signal transduction [40–43]. This interaction occurs when PtdSer binds to the Gla domain of Gas6 or Protein S in the presence of Ca²⁺ ions [40, 44]. In this context Gas6 and Protein S serve as bridging molecules for PtdSer and the TAM receptor. Adding PtdSer containing lipid membranes in the presence of TAM receptor ligand increases phosphorylation levels of TAM receptors compared to just adding ligand alone [41, 42]. This bridging interaction and signaling is important for phagocytosis of apoptotic cells exposing PtdSer.
There are a wide variety of complex downstream signaling pathways following TAM receptor phosphorylation. Detailed reviews summarizing known signaling pathways of individual TAM receptors have been published [19, 45, 46]. One of the most well characterized TAM receptor signaling pathways in macrophages is the phosphoinositide 3 kinase (PI3K)/Akt pathway. PI3K is made of a p85 regulatory subunit and a p110 catalytic subunit [47]. The intracellular kinase domain of phosphorylated Tyro3, Axl and MerTK can bind the p85 subunit of PI3K directly [48, 49]. Alternatively, the TAM receptors can also interact with p85 using growth factor receptor-bound protein 2 (Grb2) as a bridging protein [48, 50, 51]. Following activation of PI3K through either mechanism, PI3K phosphorylates Akt. In U937-derived macrophages, it has been shown that Gas6 mediated phosphorylation of Akt leads to glycogen synthase kinase 3β (GSK3β) phosphorylation and suppression of NF-kB nuclear translocation, thereby altering gene transcription [52]. The PI3K/Akt signaling axis has been shown to play roles in macrophase activation and polarization, suggesting a role for the TAM receptors in regulating macrophase phenotype and function [53, 54].

**TAM receptor expression is influenced by macrophase polarization**

Macrophages are influenced by cytokines and factors to adopt various phenotypes and functions. “Classically activated” M1 macrophages are involved in defense against bacteria and viruses and polarize in response to granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ (IFN-γ) and microbial products such as lipopolysaccharide (LPS). These macrophages secrete pro-inflammatory cytokines and factors such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), IL-1β, IL-12, IL-15, IL-18 and nitric oxide (NO). “Alternatively activated” M2 macrophages are stimulated by factors such as macrophage colony-stimulating factor (M-CSF), IL-4, IL-13, IL-10 and dexamethasone. Secreted products of M2 macrophages include transforming growth factor β (TGF-β), IL-10, IL-13 and IL-1α. Through their functions and cytokine production, M2 macrophages have roles in tissue homeostasis, wound healing and fighting parasitic infections. In the setting of the TME, M1 macrophages play anti-tumor roles that aid in tumor immunity and M2 macrophages have pro-tumor influences that support disease progression.

Monocytes are differentiated into macrophages which are then polarized to different subtypes. Upon monocyte to macrophage differentiation, MerTK expression is up-regulated and Tyro3 levels remain unchanged [55–57]. There is conflicting evidence in the literature regarding Axl expression on M1-like and M2-like macrophages. While Tyro3 mRNA and protein are expressed in monocytes and macrophages, there is a lack of literature characterizing Tyro3 expression levels on macrophages polarized to either an M1 or M2 subtype. However, Axl and MerTK expression on M1-like and M2-like macrophages has been described in the literature and will be summarized here.

Like the evidence for monocyte-to-macrophage differentiation, there is conflicting evidence in the literature regarding Axl expression on M1-like and M2-like macrophages. Several reports have demonstrated Axl expression to be higher on M2-like macrophages. Axl
expression is increased in IL-4 and IL-13 polarized M2 macrophages compared to LPS and IFN-γ M1 polarized macrophages in murine bone marrow-derived macrophages (BMDMs) [58]. AXL transcripts levels are higher in M2-like human monocyte-derived macrophages polarized with M-CSF than M1-like polarized with GM-CSF [59]. In human monocyte-derived macrophages, AXL mRNA is induced following treatment with immunosuppressive M2-stimulant dexamethasone [56]. In contrast, however, there is also evidence that Axl expression is higher on M1-like macrophages. Following treatment with M1-stimulant LPS, BMDMs have increased Axl expression [41]. This study also observed Axl downregulation following dexamethasone treatment to induce M2-like macrophages. Pro-inflammatory viral triggers such as IFN-α and poly(I:C) also stimulate Axl expression on human monocyte-derived macrophages [41]. Thus, it is possible that Axl expression on M1 versus M2 macrophages may differ model-to-model based on specific experimental conditions, such as source of monocytes and method of polarization.

MerTK expression has consistently been shown to be higher in immunosuppressive, M2-like macrophages than unstimulated and M1-like macrophages. It has been reported that MerTK mRNA transcript levels are higher in IL-4 and IL-13 M2 polarized BMDMs than LPS and IFN-γ M1 polarized BMDMs [58]. Monocyte-derived human macrophages treated with M2-stimulants M-CSF, IL-4, IL-10 or CD5L have higher MerTK protein levels than untreated macrophages or those stimulated with M1-stimulant GM-CSF, LPS, IFN-γ, IFN-α or poly(I:C) [60–63]. MerTK is also upregulated in human monocyte-derived macrophages following stimulation with dexamethasone and corticosteroids hydrocortisone and aldosterone, supporting MerTK expression in immunosuppressive, anti-inflammatory M2-like macrophages [41, 56, 60, 62, 64].

TAM receptor signaling inhibits M1 polarization and induces M2 polarization

While LPS and IFN-γ are the standard M1 macrophage inducers and IL-4 and IL-13 are the standard M2 macrophage polarizing agents for in vitro polarization, there are many other proteins and stimulants that can skew macrophage polarization. TAM receptor signaling has been shown to play a role in shifting macrophage polarization by dampening M1 polarization and inducing M2 polarization (Fig. 2).

TAM receptor signaling has been shown to reduce M1 polarization, with most evidence showing a decrease in M1-associated cytokine secretion (e.g., TNF-α, IL-6 and IL-1β) following TAM receptor activation by Gas6 or Protein S. In LPS-stimulated U937-derived macrophages, Gas6/MerTK signaling decreases secretion levels of TNF-α, IL-6 and IL-1β [52]. Similarly, Gas6/MerTK signaling inhibits TNF-α and IL-6 secretion in human monocytes/macrophages [52]. In an independent study, MerTK activation was shown to inhibit TNF-α production by LPS-stimulated mouse macrophages [65]. Additionally, exogenous Gas6 treatment on phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages decreases TNF-α, IL-1β and IL-6 mRNA and protein levels, providing further evidence that TAM receptor signaling blocks M1 polarization [66]. It has been shown that Protein S activation of either MerTK or Tyro3 inhibits LPS and IFN-γ induced M1 polarization of peritoneal and tumor-derived mouse macrophages, indicated by decreased expression of M1 marker genes Il1, Il6, Cdb6 and Tnf [67]. Stimulation of mouse peritoneal macrophages with Gas6 or Protein S decreases M1-associated inflammatory gene expression of IL-1β, IL-6 and TNF-α [68]. Additionally, inhibition of Gas6 or Protein S with neutralizing antibodies increases expression levels of these M1-associated pro-inflammatory genes [68]. In an invasive pulmonary aspergillosis (IPA) model, it has been shown that an anti-Axl antibody increases the number of M1 macrophages [69]. This was measured by an increase whole-lung Inos transcript levels, a marker of M1 activation and a decrease in M2 activation markers Arg1 and Fizz1. Contradictory to these studies, inhibition of Axl with a monoclonal antibody has been shown to decrease M1-associated inflammatory factors IL-6, TNF-α and G-CSF production by tumor associated macrophages in MDA-MB-231 xenograft breast cancer models, suggesting Axl promotes M1 polarization some cases [70].

In addition to effects on M1 polarization, TAM receptor signaling has also been shown to promote pro-tumor M2 macrophage polarization. Gas6 mediated MerTK signaling in the RAW264.7 murine macrophage cell line increases mRNA and protein levels of M2-associated genes Arg2 and VEGF, as well as mRNA levels of Arg1 [71]. Recently, it was discovered that mineral trioxide aggregate (MTA) polarizes THP-1 cells towards an M2 phenotype in an Axl signaling-dependent manner. The MTA-induced M2 polarization, indicated by increased M2 marker CD206 and M2-associated secreted cytokines IL-10, TGF-β and VEGF was blocked by the Axl small molecule inhibitor R428 [72]. M1 polarized THP-1 macrophages treated with Gas6 have increased protein levels of the M2 marker CD206 and mRNA levels of M2-associated genes CD206 and IL10 [73]. These macrophages also have decreased protein levels of M1 marker CD11b and increased STAT6 phosphorylation, an inducer of M2 polarization. Mice null for Galectin-3, a newly discovered MerTK ligand, have a reduced IL-4 and IL-13 induced M2 polarization, suggesting galectin-3 also skews macrophage polarization towards
an M2-like phenotype [74]. Taken together, these data suggest that the TAM receptors play a role in shifting macrophage polarization away from an M1-like phenotype and towards an M2-like phenotype.

Efferocytosis and M2-like polarization is tumor-promoting
A major role of macrophages is clearance of apoptotic cells, a process known as efferocytosis. Dendritic cells and specialized epithelial cells and fibroblasts also have the ability to efferocytose. This mechanism is enacted to maintain tissue homeostasis and prevent induction of inflammation by secondary necrosis. Under normal physiology, lack of efferocytosis is disadvantageous in many cases because secondary necrosis releases immunogenic components that can lead to chronic inflammation and autoimmune disorders [75]. However, in a cancer setting efferocytosis is pro-tumor as it induces a wound-healing immunosuppressive phenotype. Consistent with this phenotype, M2-like macrophages have a greater capacity for efferocytosis than M1-like macrophages [60, 76–79].

Due to its tumor-promoting role, the efferocytosis pathway is an exciting and new potential therapeutic target [16].

Efferocytosis is initiated by signals from the apoptotic cell that then promote cytoskeletal rearrangement and nuclear receptor signaling in the efferocytosing macrophage. “Find-me” signals promote attraction of monocytes and macrophages. Some well-established “find-me” signals are adenosine triphosphate (ATP), uridine triphosphate (UTP), lysophosphatidylcholine (LPC), fractalkine and spingosine 1-phosphate (S1P) which are released from the cell in a caspase-regulated manner during apoptosis [80–83]. Apoptotic cells also display “eat-me” signals on their surface for macrophages to tether to. The most characterized “eat-me” signal is the lipid moiety PtdSer. Healthy cells sequester PtdSer on the inner leaflet by action of flippase enzymes. During apoptosis, caspase activity inactivates the flippase adenosine triphosphatase type 11C (ATP11C) and activates the scramblase Xk-Related Protein 8 (Xkr8) allowing PtdSer exposure on the outer leaflet of the cell membrane [84, 85].

The TAM receptors, among others such as phosphatidylserine receptor (PSR), CD36, Tim4, BA11 and αvβ3 integrin bind PtdSer to tether the macrophage to the apoptotic cell [86–91]. As discussed in a previous section, Gas6 and Protein S serve as bridging molecules between PtdSer and the TAM receptors (Fig. 3). PtdSer binds the Glu end of Gas6 and Protein S while the TAM receptors bind their LG domains. This allows macrophages to attach to the apoptotic cell prior to phagocytosis [92].

Following TAM receptor apoptotic cell tethering, cytoskeletal rearrangements induce phagocytosis. Evidence for the mechanism of cytoskeletal rearrangement by MerTK-mediated efferocytosis has been described. Following apoptotic cell binding, the phosphorylated tyrosine kinase domain of MerTK facilitates phosphorylation of Vav1 [93]. The binding of the cytoplasmic tail to Vav1 is phosphotyrosine-independent, although MerTK activation is required for Vav1 phosphorylation and release. Vav1 is a guanine nucleotide-exchange factor (GEF) that can stimulate guanosine diphosphate (GDP) to guanosine triphosphate (GTP) exchange. When phosphorylated, Vav1 activates Rho family members Rac1, Cdc42 and RhoA [93, 94]. These proteins temporally and spatially regulate cytoskeleton dynamics, which promote engulfment of the apoptotic cell [95–97].

Following engulfment of apoptotic cells, nuclear receptors are engaged in response to an increase in metabolic demand from the ingested cellular components (Fig. 4). Specifically, retinoid X receptors (RXRs) form heterodimers with peroxisome proliferator activated receptors (PPARs), and liver X receptors (LXRs) that have important roles in efferocytosis and other macrophage functions [98, 99]. These nuclear receptors have been shown to be associated with transcription of genes controlling and associated with M2 polarization [100–104]. This
evidence suggests that nuclear receptor signaling following efferocytosis further polarizes macrophages to an M2-like phenotype. Notably, the process of efferocytosis itself promotes increased secretion of immunosuppressive cytokines associated with M2-like macrophages such as IL-10, TGF-β, IL-4 [105–107]. Apoptotic cell clearance by macrophages also decreases secretion of immune-stimulating cytokines associated with M1-like macrophages such as TNF-α, IL-1β and IL-12 [105, 107]. This evidence indicates that efferocytosis further promotes M2 polarization and function that can drive disease progression.

Nuclear receptors also regulate gene expression of machinery necessary for efferocytosis such as MERTK and AXL. PPAR-δ, PPAR-γ and RXRα have been shown to increase MERTK and AXL transcription in macrophages [108–111]. Pharmacologic inhibition or knockout of these nuclear receptors impairs apoptotic cell phagocytosis. However, in a separate study, MerTK and Gas6 expression was shown to increase with a PPAR-γ antagonist [112]. This conflicting evidence may reveal a further layer of MerTK regulation by nuclear receptors depending on the macrophage phenotype. Following apoptotic cell phagocytosis, LXR signaling is also induced [113]. MERTK, but not TYRO3 or AXL, is a direct target gene of LXR nuclear receptors. As a result, MERTK transcription is increased following efferocytosis, creating a positive feedback loop. It has also been shown that MerTK signaling increases LXR abundance, which could potentiate this loop further [114].

One of the non-cytokine secreted products following apoptotic cell clearance by macrophages is hepatocyte growth factor (HGF) [115]. Shown in RAW 264.7 cells, this increase in HGF production was found to be mediated by MerTK (but not Axl or Tyro3) activation via RhoA-mediated signaling [116, 117]. Gas6/MerTK stimulated HGF production was found involve the same signaling pathway and was able to stimulate wound repair and cell growth of LA-4 epithelial cells [118]. While these studies speculated implications with alveolar macrophages, it remains of interest if these findings can translate to tumor associated macrophages since HGF can promote disease through HGF/c-Met signaling in a number of cancers [119].

While all three TAM receptors mediate efferocytosis in macrophages MerTK has been found to be essential to the process. MerTK was first identified as a phagocytic receptor when it was observed that Mertk deficient mice had dramatically reduced clearance of apoptotic thymocytes [120]. While apoptotic cell clearance by macrophages is nearly abolished in Mertk deficient mice, it is also substantially decreased in Axl and Tyro3 single knockout mice [57]. Additionally, RAW264.7 macrophages treated with an anti-MerTK antibody have impaired phagocytosis of apoptotic thymocytes [113]. Although Axl and Tyro3 mediate efferocytosis in macrophages, they may play more dominant roles in efferocytosis by dendritic cells [57, 121]. It has also been proposed that macrophage efferocytosis is dominated by MerTK in an immunosuppressive setting, whereas Axl is important in an inflammatory setting, dominating efferocytosis [41].

**TAM receptor inhibition as a therapy for cancer**

Given what is known about the role of the TAM receptors in macrophages, key members of the TME, TAM receptor inhibition is a strong candidate for an anti-cancer therapy. TAM receptor inhibition may impair pro-tumor effects of M2-like macrophages by blocking efferocytosis.
Since TAM receptor activation also skews macrophages polarization from an M1 to M2 phenotype, TAM receptor inhibition would decrease M2 characteristics of tumor-associated macrophages. As M2 macrophages have tumor-promoting roles involving cancer progression and immune suppression, impairing M2 polarization will slow disease progression. In addition to dampening M2 polarization, TAM receptor inhibition will increase polarization of M1-like macrophages in the TME. Since M1 macrophages have anti-tumor functions, shifting the balance of macrophages towards an M1 phenotype is beneficial in cancer. For example, in ovarian cancer the ratio of M1 to M2 tumor-associated macrophages decreases with increasing cancer stage, and a high ratio correlates with increased survival [122]. Similarly, pediatric classical Hodgkin Lymphoma patients with a predominant M1 polarization have a better overall survival [123].

There have been a few studies showing that MerTK inhibition, specifically on macrophages, is an effective anti-cancer therapy. In a number of different cancer types and tumor models, there is increased tumor macrophage infiltration following radiation therapy and these macrophages have been suggested to confer radio-sensitivity to cancer cells [124–126]. MerTK on tumor associated macrophages has been shown to play a role in radiation therapy resistance. Following radiation therapy in a colorectal cancer mouse model, MerTK, Protein S and Gas6 are upregulated in tumor associated macrophages [127]. Neither Axl nor Tyro3 expression are changed. In this study, Mertk knockout mice had a stronger overall survival following radiation therapy than wild type mice. This suggests that targeting MerTK on tumor associated macrophages may impair resistance following radiation therapy.

Inhibition of MerTK on leukocytes decreases tumor growth and metastasis in in vivo models of breast cancer, melanoma and colon cancer [128]. Mertk knockout mouse had decreased levels of the wound-healing cytokine IL-10 and increased levels of inflammatory cytokines IL-12 and IL-6 levels. Specific to the CD11b+ macrophage population, IL-6 expression was increased compared to the WT mice. These changes in cytokine expression indicates a more M1-like macrophage phenotype. These Mertk knockout mice also had higher levels of CD8+ T cells following tumor inoculation, suggesting the change in cytokine expression may help promote anti-tumor immunity. This suggests that targeting MerTK on leukocytes, including macrophages, has multiple arms of anti-cancer activity.

In addition to impacting macrophage polarization and function, the TAM receptors have been shown to drive disease progression through their direct roles in growth, migration and therapy resistance of cancer cells. In certain cell line and mouse models for glioma, Kaposi sarcoma, mesothelioma, and non-small cell lung cancer, Axl inhibition decreases tumor growth [129–132]. Tyro3 is a proposed target in ovarian cancer due to its role in taxol resistance [133]. Additionally, siRNA silencing of Tyro3 has been shown to reduce proliferation in breast cancer cell lines [134, 135]. In non-small cell lung cancer, MerTK expression correlates with chemotherapy resistance, proliferation and migration [132, 136]. Thus, for some cancers the TAM receptors may serve as a strong dual target to impair both the tumor cells as well as tumor-associated macrophages.
Due to similarities in structure in the three TAM receptors, it is difficult to develop inhibitors specific for a single TAM receptor. Some TAM receptor inhibitors have specificity for other RTKs. However, targeting multiple TAM receptors may be advantageous as MerTK upregulation as a result of silencing or inhibiting Axl has been observed in several cancer models, suggesting the MerTK mediates resistance to treatments targeting Axl [137]. Additionally, as all three TAM receptors mediate M2 polarization and efferocytosis by macrophages, targeting multiple TAM receptors may have a stronger anti-cancer effect.

R428 is a small molecule inhibitor of Axl widely used in preclinical studies and in a number of clinical trials (see Table 2). While this inhibitor most potently inhibits Axl, there is off-target inhibition of other kinases including MerTK and Tyro3 [138]. R428 has demonstrated anti-cancer activity in a number of preclinical studies. For example, R428 decreases invasion and growth of the esophageal adenocarcinoma cell line OE33, as well as increases sensitivity to Lapatinib [139]. This inhibitor also induces apoptosis in freshly isolated B-cell chronic lymphocytic leukemia and at high doses overcomes stroma-mediated protection [140]. R428 blocks growth and migration of erlotinib resistant tongue squamous cell carcinoma HN5 cells [141]. Axl is overexpressed in metformin resistance prostate cancer LNCaP cells and Axl inhibition with R428 re-sensitized these resistant cells to metformin [142]. In vivo, R428 slows tumor growth of mice subcutaneously injected with chronic myeloid leukemia (CML) cell lines [143]. It has also been shown that R428 in combination with paclitaxel reduces proliferation of uterine serous cancer xenograft models [144]. While these studies focused on the effect of R428 on cancer cells and disease progression, it remains unknown if R428 inhibition of Axl on macrophages contributed to the positive results in these studies. Other Axl inhibitors are currently being used in preclinical studies and demonstrate therapeutic effects utilizing in vitro and in vivo cancer models (see Table 1).

Several MerTK inhibitors are also in development (see Table 1). UNC569, UNC1062, UNC1666, UNC2025 and UNC2250 are MerTK small molecule inhibitors that have demonstrated anti-cancer activity in preclinical models [145–150]. UNC569 induces apoptosis, improves sensitivity to cytotoxic chemotherapy and reduces colony formation in ALL cell lines [146]. UNC569 has also been utilized in vivo to study phagocytosis by retinal pigment epithelium cells [151]. UNC1062, as well as UNC569, induces apoptosis and decreases cell growth in AML cell lines [147]. UNC1666 is a dual MerTK and FLT3 inhibitor that reduces colony formation in MerTK- or FLT3-ITD- expressing AML cell lines [148]. UNC1062 and UNC1666 have poor oral bioavailability, so their clinical utility may be limited [148, 149]. UNC2025 is an orally bioavailable dual MerTK and

| TAM Targeting Drug (Drug Type) | Target(s) | Outcomes in cancer models |
|-------------------------------|-----------|---------------------------|
| 2,4-diaminopyrimidine-5-carboxamide analogs (Small molecule) | Tyro3 | Not reported. |
| “Compound 47” (Small molecule) | Tyro3, IGF-1R, EphA2 | Anti-cancer properties in HCC cell lines and xenograft models [158]. |
| DP-3975 (Small molecule) | Axl | Anti-cancer properties in mesothelioma cell lines [131]. |
| GL21.T (RNA aptamer) | Axl | Anti-cancer properties in a glioblastoma and a lung cancer cell line and mouse models [164]. |
| Mer590 (Monoclonal antibody) | MerTK | Anti-cancer properties in lung cancer cell lines [157]. |
| NPS-1034 (Small molecule) | Axl, Met | Anti-cancer properties in EGFR inhibitor resistant lung cancer cell lines and xenograft models [165]. |
| Spiroindoline-based analogs (Small molecule) | Tyro3 | None reported. |
| UNC569 (Small molecule) | MerTK, Axl, Tyro3 | Anti-cancer properties in ALL and AML cell lines [146, 147]. |
| UNC1062 (Small molecule) | MerTK | Anti-cancer properties AML cell lines [147]. |
| UNC1666 (Small molecule) | MerTK, Flt3 | Reduces colony formation in AML cell lines [148]. |
| UNC2025 (Small molecule) | MerTK, Flt3 | Anti-cancer properties in non-small cell lung cancer, leukemia and glioblastoma mouse models [152–155]. |
| UNC 2250 (Small molecule) | MerTK | Anti-cancer properties in mantle cell lymphoma cell lines and mouse models [166]. |
| UNC2541 (Small molecule) | MerTK | None reported. |
| YW327.652 (Monoclonal antibody) | Axl | Anti-cancer properties in lung and breast cancer mouse models [70]. |

TAM receptor-specific targets are bolded.
FLT3 inhibitor [149]. In preclinical studies it has been demonstrated to have therapeutic effects in non-small cell lung cancer, leukemia and glioblastoma models [152–155]. Interestingly, one study focused on glioma-associated macrophages and microglia and found that UNC2025 alone and in combination with radiotherapy decreased the number of CD206+ M2 macrophages [155]. This supports the hypothesis that blocking M2 polarization via targeting TAM receptor signaling may impair disease progression. More recently, a macrocyclic pyrimidine, UNC2541, was synthesized and found be selective for MerTK over the other TAM receptors and FLT3 [156]. Mer590, a monoclonal antibody against MerTK, decreased MerTK expression in several lung cancer cell lines as well as increased apoptosis, sensitivity to carboplatin and decreased colony formation [157].

Although less studied, synthesis of Tyro3 inhibitors has also been explored (see Table 1). E/Z 6-Chloro-3-(3-trifluoromethyl-benzyliden)-1,3-dihydroindol-2-one (“Compound 47”) has been shown to block Tyro3 phosphorylation HuH7 cells [158]. Additionally, spiroindoline-based and 2,4-diaminopyrimidine-5-carboxamide inhibitors of Tyro3 have been made [159–161].

Small molecule inhibitors, antibody-drug conjugates, Axl-Fc fusion proteins and CAR-T therapies for the TAM receptors are in clinical trials. Summarized in Table 2, most clinical trials have primarily aimed to target Axl because of Axl’s known role in driving disease progression through expression on cancer cells, although some inhibitors also inhibit MerTK and other RTKs with lower affinity. Active trials are in Phase I or II with some trials studying combinational effects with other cancer treatments. A Phase I clinical trial of ASLAN-002 with published results has been completed, and it was determined that 300 mg twice daily is a well-tolerated dose and is recommended for Phase II [162]. The most commonly reported adverse events were nausea, fatigue and constipation, and atrial fibrillation was reported as a dose limiting toxicity. Cabozantinib is a multi-kinase small molecule inhibitor that targets Axl, c-Met, VEGFR2, RET, KIT, and FLT3. This therapy is FDA-approved for advanced renal cell carcinoma.

Table 2 Summary of clinical trials targeting TAM receptor activity

| TAM Targeting Drug (Drug Type) | Target(s) | Condition(s) | ClinicalTrials.gov Identifier(s) |
|-------------------------------|-----------|--------------|----------------------------------|
| AVB-56–500 (Axl-Fc fusion protein) | Gas6      | Ovarian Cancer | NCT03401528                       |
|                              |           | Epithelial Ovarian Cancer | NCT03607955                       |
|                              |           | Primary Peritoneal Carcinoma | NCT03639246                       |
| ASLAN-002/BMS-777607 (Small molecule) | Met, RON, FLT3, Axl | Advanced or Metastatic Solid Tumors | NCT00605618, NCT01721148 [162] |
| BA3011/CAB-AXL-ADC (Antibody-drug conjugate) | Axl      | Solid Tumor | NCT03425279                      |
|                              |           | Non-Small Cell Lung Cancer |                                   |
|                              |           | Castration-Resistant Prostate Cancer |                                   |
|                              |           | Pancreatic Cancer |                                   |
| Bemcentinib/BGB324/R428 (Small molecule) | Axl      | Advanced or Metastatic Solid Tumors | NCT02424617, NCT02488408, NCT02872259, NCT02922777, NCT03184558, NCT03184571, NCT03649321, NCT03654833 |
| BPI-9016 M (Small molecule) | Axl, Met  | Solid Tumors | NCT02478866                      |
|                              |           | Non-Small Cell Lung Cancer | NCT02929290                       |
| CCT301 (CAR-T) | Axl       | Renal Cell Carcinoma | NCT03393936                      |
| INCB081776 (Small molecule) | Axl, MerTK | Advanced Solid Tumors | NCT03522142                      |
| MRX-2843 (Small molecule) | MerTK, FLT3 | Advanced or Metastatic Solid Tumors | NCT03510104                      |
| ONO-7475 (Small molecule) | Axl, MerTK | Advanced or Metastatic Solid Tumors | NCT03762727, NCT03510104          |
|                              |           | Acute Leukemia |                                   |
| TP-0903 (Small molecule) | Axl       | Advanced Solid Tumors | NCT02729298                      |
|                              |           | Chronic Lymphocytic Leukemia |                                   |
|                              |           | Small Lymphocytic Lymphoma |                                   |
|                              |           | EGFR Positive Non-small Cell Lung Cancer |                                   |
|                              |           | Colorectal Carcinoma |                                   |
|                              |           | Recurrent Ovarian Carcinoma |                                   |
|                              |           | BRAF-Mutated Melanoma |                                   |

TAM receptor-specific targets are bolded. Where available, published results are cited.
hepatocellular carcinoma and medullary thyroid cancer. The most commonly reported adverse events for this inhibitor are diarrhea, palmar-plantar erythrodysesthesia, fatigue, nausea, decreased appetite, hypertension, vomiting, weight loss, and constipation [163].

Conclusions
When a drug is administered, all of the cells in the microenvironment are impacted by the drug, not just the cancer cells. While current clinical trials are aimed at targeting the tumor cells, it is of interest if targeting the macrophages will contribute to the results of these trials. Given the strong evidence that the TAM receptors on macrophages have tumor-promoting roles of promoting M2 polarization and efferocytosis, it is possible that targeting the TAM receptors on macrophages will be an effective therapy for treating different types of cancers. More preclinical evidence and clinical studies with a focus on macrophages could help determine the therapeutic relevance of targeting the TAM receptors as a cancer treatment.

Abbreviations
ATP: Adenosine triphosphate; ATP11C: Adenosine triphosphatase 11C; BMDM: Bone marrow-derived macrophages; CML: Chronic myeloid leukemia; ECM: Extracellular matrix; EGF: Epidermal growth factor; FNIII: Fibronectin type III; GDP: Guanosine diphosphate; GEF: Guanine nucleotide-exchange factor; GSK3γ: Glycogen synthase kinase 3B; GTP: Guanosine triphosphate; HGF: Hepatocyte growth factor; IFN: Interferon; IgL: Immunoglobulin-like; IL: Interleukin; IPA: Invasive pulmonary aspergillosis; LG: Laminin G; MCC: Macrophage colony-stimulating factor; M-CSF: Macrophage colony-stimulating factor; MTA: Mineral trioxide aggregate; NO: Nitric oxide; PI3K: Phosphoinositide 3 kinase; PMA: Phorbol 12-myristate 13-acetate; PPAR: Peroxisome proliferator activated receptor; PSR: Phosphatidylserine receptor; PtdSer: Phosphatidylserine; RTK: Receptor tyrosine kinase; RXRα: Retinoid X receptor;apa; S1P: Siponosine 1-phosphate; SHBP: Sex hormone binding protein; TAM Receptors: Tyro3, Axl and MerT; TKD: Tyrosine kinase domain; TME: Tumor microenvironment; TNF: Tumor necrosis factor; Tulp-1: Tumour-like protein 1; UTP: Uridine triphosphate; WT: Wild type; Xkr8: Xk-Related protein 8

Acknowledgements
We would like to thank Timothy H. Phelps, Professor and Medical Illustrator at Johns Hopkins University, for generating the figures presented in this review. We thank Amber de Groot for providing critical feedback to the manuscript. We also thank members of the Pienta Lab and the Brady Urological Institute for thoughtful feedback.

Funding
This work is supported by NCI grants U54CA143803, CA163124, CA093900, and CA14305 as well as the Prostate Cancer Foundation, the Patrick C. Walsh Fund and a gift from the Stutt family.

Availability of data and materials
Not applicable.

Authors’ contributions
KVM wrote the manuscript. SRA and KJP revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA. 2The James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD, USA. 3Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA. 4Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.

Received: 4 February 2019 Accepted: 2 May 2019
Published online: 14 May 2019

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019.
2. Valkenburk KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366–81.
3. Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201–18.
4. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205–15.
5. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment supportive of tumor survival and metastasis. Cancer Cell Microenviron. 2015;2(1).
6. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948908.
7. Gordon S, Martinez-Pomares L. Physiological roles of macrophages. Pflugers Arch. 2017;469(3–4):365–74.
8. Elhelu MA. The role of macrophages in immunology. J Natl Med Assoc. 1983;75(3):314–7.
9. Kodelja V, Müller C, Tenorio S, Schebesch C, Orfano C, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology. 1997;197(5):478–93.
10. Jetten N, Verbruggen N, Gijbels MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis. 2014;17(1):109–18.
11. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899–909.
12. Lepique AP, Daghastiani KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res. 2009;15(13):4391–400.
13. Han Q, Shi H, Liu F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016;34:101–6.
14. Finkenagel F, Reintz S, Lieber S, Adhikary T, Wortmann A, Hoffmann N, et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016;7(46):75339–52.
15. Vaught DB, Stanford JC, Cook RS. Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis. Cancer Cell Microenviron. 2015;2(1).
16. Werfel TA, Cook RS. Efferocytosis in the tumor microenvironment. Semin Immunopathol. 2018.
17. Lu Q, Gore M, Zhang Q, Camensich T, Boast S, Casagrande F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature. 1999;398(6729):723–8.
18. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the tyro 3 family. Science. 2001;293(5528):306–11.
19. Linger RMA, Keating AK, Earp HS, Graham DK. TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer. Advances in Cancer Research 2008. p. 35–83.
20. Liu E, Hjelle B, Bishop JM. Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1988;85(15):5952–6.

21. O’Byran JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016–31.

22. Liu E, Mayer BI, Hanafusa T, Hanafusa H. A novel oncogene, v-ryk, encoding a truncated receptor tyrosine kinase is transduced into the RBL30 virus without loss of viral sequences. J Virol. 1992;66(10):5975–87.

23. Graham DK, Dawson TL, Mullany DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 1994;5(6):647–57.

24. Polvi A, Armstrong E, Lai C, Huebner K, Spritz RA, et al. The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25. Gene. 1993;134(2):289–93.

25. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988;54(6):787–93.

26. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C dependent proteins related to protein-S, a negative Coregulator in the blood-coagulation Cascade. Mol Cell Biol. 1993;13(8):4976–85.

27. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J Virol. 1992;66(10):5975–87.

28. DiSipio RG, Davie EW. Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. J Biochemistry. 1985;18(5):899–904.

29. Walker FJ. Regulation of activated protein C by protein S. the role of phospholipid in factor Va inactivation. J Biol Chem. 1981;256(21):11128–31.

30. Lundwall A, Dackowski W, Cohen E, Shafer M, Mahr A, Dahlback B, et al. Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc Natl Acad Sci U S A. 1986;83(18):6716–20.

31. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl, a receptor tyrosine kinase stimulated by the vitamin K-dependent protein gamma-carboxyglutamic acid protein containing protein from bovine and human plasma. J Biochemistry. 1978;15(2):396–9.

32. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation protein factor S and its relative, Gas6, are ligands for the tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80(4):661–70.

33. Lew ED, Oh J, Burrola PG, Lai C, Zagorska A, Traves PG, et al. Differential regulation of activated protein C by protein S. the role of phospholipid in factor Va inactivation. J Biol Chem. 1981;256(21):11128–31.

34. Nomura K, Vilalta A, Allendorf DH, Hornik TC, Brown GC. Activated microglia regulate of activated protein C by protein S. the role of phospholipid in factor Va inactivation. J Biol Chem. 1978;253(13):5005–16.

35. Caberoy NB, Alvarado G, Bigcas JL, Li W. Galectin-3 is a new MerTK-specific ligand for phagocytosis. EMBO J. 2010;29(23):3898–908.

36. Caberoy NB, Zhou Y, Li W. Tubby and tubby-like protein 1 are new MerTK specific gene 6. Nature. 1995;373(6515):623–6.

37. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ. Characterization of a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J Virol. 1992;66(10):5975–87.

38. Heiring C, Dahlback B, Muller YA. Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol Chem. 2004;279(8):6952–8.

39. Kasikara C, Kumar S, Kimani S, Tsou WI, Geng K, Davra V, et al. Axl, a receptor tyrosine kinase function. Nat Immunol. 2014;15(10):920–8.

40. Kasikara C, Kumar S, Kimani S, Tsou WI, Geng K, Davra V, et al. Phosphatidylinerseinsing by TAM receptors regulates AKT-dependent Chemoresistance and PD-L1 expression. Mol Cancer Res. 2017;15(6):753–64.

41. Tsou WI, Nguyen KQ, Calabrese DA, Garforth SJ, Annes AL, Smirnov SV, et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem. 2014;289(7):2570–593.

42. Nakano T, Ishimoto Y, Kishino J, Umeda M, Inoue K, Nagata K, et al. Cell adhesion to phosphatidylinositer mediated by a product of growth arrest-specific gene 6. J Biol Chem. 1997;272(7):4041–4.

43. Zagorska A, Traves PG, Lew ED, Dranfield I, Lemke G. Differentiation of TAM receptor tyrosine kinase function. Nat Immunol. 2004;15(10):920–8.

44. Kasikara C, Kumar S, Kimani S, Tsou WI, Geng K, Davra V, et al. Phosphatidylinositeraseinsing by TAM receptors regulates AKT-dependent Chemoresistance and PD-L1 expression. Mol Cancer Res. 2017;15(6):753–64.

45. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylinositeraseinsing receptor tyrosine kinases gone away in cancer. Nat Rev Cancer. 2014;14(12):769–85.

46. Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res. 2013;19(19):5275–80.
70. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29(8):2554–64.

71. Kim SY, Lim EJ, Yoon YS, Ahn YH, Park EM, Kim HS, et al. Liver X receptor and STAT1 cooperate downstream of Gata/Mer to induce anti-inflammatory arginase 2 expression in macrophages. Sci Rep. 2016;6:29673.

72. Yeh HW, Chiang CF, Chen PH, Su CC, Wu YC, Chou L, et al. Axl involved in mineral trioxide aggregate induces macrophage polarization. J Endod. 2018.

73. Nam SH, Lee D, Lee HM, Song DG, Jung JW, et al. Lysyl-tRNA synthetase-expression colon spheroids induce M2 macrophage polarization to promote metastasis. J Clin Invest. 2018;128(1):5034–55.

74. MacKinnon AC, Farnsworth JL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180(4):2650–8.

75. Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 2010;584(22):4491–9.

76. de Oliveira Fulco T, Andrade PR, de Mattos Barbosa MG, Pinto TG, Ferreira PF, Ferreira H, et al. Effect of apoptotic cell recognition on macrophage polarization and mycobacterial persistence. Infect Immun. 2014;82(9):3968–79.

77. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 macrophages phagositize rituximab-opsorized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182(7):3654–9.

78. Heasman SJ, Giles KM, Rossi AG, Allen JE, Haslett C, Dransfield I. Interferon alpha induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a come-and-get-me signal. J Immunol. 2009;182(7):3686–91.

79. Banerjee S, Xie N, Cui H, Tan Z, Yang S, Icyuz M, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol. 2013;190(12):6542–7.

80. Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated engulfment. Cell. 2011;147(7):1442–51.

81. Rossiter T, Menendez-Gutierrez MP, Cedenilla M, Ricote M. Retinoid X receptors in macrophage biology. Trends Endocrinol Metab. 2013;24(9):460–8.

82. Kimura T, Nada S, Takegahara N, Okuno T, Nijima K, Kang S, et al. Polarization of M2 macrophages requires Lmtmr1 that integrates cytokine and amino-acid signals. Nat Commun. 2016;7:13130.

83. Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castillero A, et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol. 2008;22(6):1394–402.

84. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Moel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116–20.

85. Bouhlet MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137–43.

86. Penna F, Mirkin GA, Vera M, Cevey A, Gonzalez CD, Gomez MI, et al. Treatment in vitro with PPARalpha and PPARgamma ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice. Biochim Biophys Acta. 2015;1852(3):939–49.

87. Voil RE, Hermann M, Roth EA, Stach C, Kalden JR, Girkanote M. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–1.

88. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, et al. Effecrocytosis produces a promestastic landscape during postpartum mammary gland involution. J Clin Invest. 2014;124(11):4737–52.

89. Pirghaj MG, Soudi S, Ghanbarian H, Bolandi Z, Namaki S, Hashemi SM. Effect of effecrocytosis of apoptotic mesenchymal stem cells (MSCs) on C57BL/6 peritoneal macrophages function. Life Sci. 2018.

90. Savage JC, Jay T, Godini E, Quigley C, Mariani MM, Malm T, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer’s disease. J Neurosci. 2015;35(16):6532–43.

91. Maji G, Sarang Z, Cosimos K, Zahnuczy C, Fesus L, Pirghaj MG, et al. PPAR- dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur J Immunol. 2016;46(3):613–23.

92. Roszer T, Menendez-Gutierrez MP, Lefterova MI, Alameda D, Nunez V, Lazar MA, et al. Autophagy in kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency. J Immunol. 2011; 186(1):621–31.

93. Mukundan L, Odegaard JJ, Morel CR, Henecka JE, Mwangi JW, Ricardo-Gonzalez RR, et al. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med. 2009;15(11):1266–72.

94. Zizzo G, Cohen PL. The PPAR-gamma antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the Met/TK/Gas6 axis: a key role for PPAR-gamma in human macrophage polarization. J Inflamm (Lond). 2015;12:36.

95. NAC, Bensinger SJ, Hong C, Beccario S, Bradley MN, Zelcer N, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31(2):245–58.

96. Choi JY, Seo JY, Yoon YS, Lee YJ, Kim HS, Kang JL. Mer signaling increases the effect of multiple anticancer therapies. Oncogene. 2010;29(38):5254–64.

97. Kim SY, Kim S, Bae DJ, Park SY, Lee GY, Park GM, et al. Coordinated balance of Rac1 and RhoA plays key roles in determining phagocytic appetite. PLoS One. 2017;12(4):e0174603.

98. Allen WE, Zicha D, Ridley AJ, Jones GE. A role for Cdc42 in macrophage chemotaxis. J Cell Biol. 1998;141(19):1147–57.

99. Allen WE, Jones GE, Pollard JW, Ridley AJ. Rho, Rac and Cdc42 regulate actin organization and cell adhesion in macrophages. J Cell Sci. 1997;110( Pt 6):707–20.

100. Han CZ, Ravichandran KS. Metabolic connections during apoptotic cell engulfment. Cell. 2011;147(7):1442–5.

101. Rosser T, Menendez-Gutierrez MP, Cedenilla M, Ricote M. Retinoïd X receptors in macrophage biology. Trends Endocrinol Metab. 2013;24(9):460–8.

102. Kimura T, Nada S, Takegahara N, Okuno T, Nijima K, Kang S, et al. Polarization of M2 macrophages requires Lmtmr1 that integrates cytokine and amino-acid signals. Nat Commun. 2016;7:13130.
160. Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, et al. Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of sky kinase. Bioorg Med Chem Lett. 2013;23(4):1051–5.

161. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, et al. Novel and selective spiroindoline-based inhibitors of sky kinase. Bioorg Med Chem Lett. 2012;22(1):190–3.

162. Roohullah A, Cooper A, Lomax AJ, Aung J, Barge A, Chow L, et al. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Invest New Drugs. 2018.

163. Singh H, Brave M, Beaver JA, Cheng J, Tang S, Zahalka E, et al. U.S. Food and Drug Administration approval: Cabozantinib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2017;23(2):330–5.

164. Cerchia L, Esposito CI, Camorani S, Rienzo A, Stasio L, Insabato L, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther. 2012;20(12):2291–303.

165. Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014;74(1):253–62.

166. Shi C, Li X, Wang X, Ding N, Ping L, Shi Y, et al. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma. J Hematol Oncol. 2018;11(1):43.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 1000M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions